

8. Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. *European Urology* 2018; 73(4): 485–487.
9. Rhee H, Thomas P, Shepherd B, et al. Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. *Journal of Urology* 2016; 196(4): 1261–1267.
10. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer – Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. *European Urology* 2020; 77(4): 403–417.
11. Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. *Journal of Cellular Biochemistry* 2004; 91(3): 528–539.
12. Eiber M, Fendler WP, Rowe SP, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. *Journal of Nuclear Medicine* 2017; 58(Supplement 2): 67S–76S.
13. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. *European Journal of Nuclear Medicine and Molecular Imaging* 2013; 40(4): 486–495.
14. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PRO-MISE): Proposed mITNM Classification for the Interpretation of PSMA-Ligand PET/CT. *Journal of Nuclear Medicine* 2018; 59(3): 469–478.
15. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging* 2015; 42(2): 197–209.
16. Rauscher I, Düwel C, Haller B, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. *European Urology* 2018; 73(5): 656–661.
17. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18 F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. *Molecular Imaging and Biology* 2015; 17(4): 575–584.
18. De Visschere PJL, Standaert C, Fütterer JJ, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. *European Urology Oncology* 2019; 2(1): 47–76.
19. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. *European Urology* 2016; 70(5): 829–836.
20. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging* 2017; 44(4): 678–688.
21. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. *Journal of Urology* 2016; 195(5): 1436–1443.
22. Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. *European Journal of Nuclear Medicine and Molecular Imaging* 2017; 44(6): 941–949.
23. Stejskal J, Jaskova V, Pavlicko A, et al. Diagnostika karcinomu prostaty pomocí fuzní biopsie. *Ces Urol* 2018; 22(2): 87–98.
24. Zalesky M, Stejskal J, Minarik I, et al. Porovnání detekce signifikantního a nesignifikantního karcinomu pomocí systematické a cílené fuzní MRI/TRUS biopsie prostaty. *Ces Urol* 2018; 22(2): 115–121.